Avery Therapeutics, Inc. is a pre-clinical phase biotech company that was first incorporated in 2013.

Management Team

 

Steve Goldman, M.D. – Chief Medical Officer, Co-Founder

Co-founded Avery Therapeutics and has served as Chief Medical Officer since 2013. Dr. Goldman is a board certified cardiologist and brings over 30 years of clinical and research experience to Avery Therapeutics. Dr. Goldman is co-inventor of MyCardia™ technology.

 

In addition, he brings significant experience in directing large, multi-centered clinical trials. Dr. Goldman earned his medical degree from the University of Cincinnati and completed Internal Medicine training at the University of Illinois, University of Chicago and Stanford, and his Cardiology Fellowship at Presbyterian Pacific Medical Center in San Francisco.

 

Dr. Goldman served in the US Navy and Marine Corps in Vietnam and Long Beach, CA.

 

 

Jordan Lancaster, Ph.D. – Chief Scientific Officer, Co-Founder

Co-founded Avery Therapeutics and has served as Chief Scientific Officer since 2013. Dr. Lancaster is leading product development efforts. Dr. Lancaster has expertise in cell and tissue engineering and is co-inventor of the intellectual property that is behind the company’s lead product MyCardia™. Dr. Lancaster earned his Ph.D. in Physiology from the University of Arizona.

 

 

Jen Watson Koevary, Ph.D. – Chief Operating Officer

Joined Avery Therapeutics in 2016 and brings business development and research expertise as Chief Operating Officer. Dr. Koevary is leading the commercialization strategy and operations.

 

Prior to joining Avery Therapeutics, Dr. Koevary worked in business development at the University of Arizona where she was responsible for guiding technology and business development for University startups, managing gap funding programs, and leading entrepreneurial education programs.

 

Dr. Koevary earned a Ph.D. in Biomedical Engineering from the University of Arizona and has research and consulting experience in medical imaging, materials engineering for biomedical applications and mechanical design and analysis for medical devices.

 

Scientific & Medical Advisors

 

Tim Mobley, M.B.A.

Mr. Mobley is currently the Director of Glass Core Technology at Samtec.  Mr. Mobley obtained his MBA from Wharton.  He brings expertise in technology commercialization, business strategy and relationship development to the Avery team.

 

 

Ruben Salinas, M.B.A.

Mr. Salinas is currently the CEO and President of Parasagen diagnostics.  He obtained his MBA from Harvard Business School.  Mr. Salinas has held high level positions at GE, bard and Qiagen.  He brings proven experience in growth and acquisition of medical technology companies to the Avery team.

 

Jack G. Copeland, M.D.

Dr. Copeland is the previous head of the cardiothoracic surgery program at the University of Arizona Medical Center in Tucson (retired). Dr. Copeland performed Arizona’s first heart transplant (1979), first heart-lung transplant (1985) and first U.S. implant of a pediatric ventricular assist device designed for newborns and toddlers (2000). Dr. Copeland brings years of experience in surgical approaches, patient populations, and immunology

 

 

Jeffery Frelinger, Ph.D.

He brings years of experience in the genetics and biology of major histocompatibility complex (MHC) and immune response to organ transplant to the Avery team.

 

Michael Zile, M.D.

Dr. Zile is a professor of medicine and cardiologist with appointments at the Ralph H. Johnson Department of Veterans Affairs Medical Center and the Medical University of South Carolina.  He has expertise in diastolic function and clinical trial design and management to the Avery team.

 

Groundbreaking

 

MyCardia™ is engineered using induced pluripotent stem cells (iPSCs), which were recognized with the Nobel Prize in Physiology or Medicine (2012).

Synergistic

 

MyCardia™ behaves like cardiac tissue and mimics key molecular attributes of the heart. MyCardia™ is comprised of multiple cell types. Each provides a unique therapeutic role that synergistically repairs the heart.

Biologically Active

 

MyCardia™ is the future of regenerative medicine for the heart. MyCardia™ stimulates the body's repair mechanisms to grow new blood vessels and results in development of new cardiac tissue in treated areas.